dpp-4 inhibitor and glp-1 receptor agonist combination The effect of inhibitors, agonists SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs | Cardiovascular Diabetology The mechanism of action of

doi: 10.1001/jamanetworkopen.2024.57232

The region accounts for a substantial revenue share owing to high prevalence of type 2 diabetes and obesity, strong healthcare infrastructure, and favorable reimbursement policies

doi: 10.1016/j.oret.2024.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar] 10.Hathaway JT, Shah MP, Hathaway DB, et al

GLP-1 medications have been extensively studied

In 2022, semaglutide (Ozempic, Wegovy, Rybelsus), one specific drug in the class of GLP-1 receptor antagonists, was approved in India to treat diabetes

In 1973, John Brown discovered the glucose-dependent insulinotropic polypeptide (GIP) employing peptide purification and protein sequencing, it was shown to have an incretin effect, increasing Insulin release triggered by glucose intake after oral administration [11]